TrovaGene Inc (TROV) was Downgraded by Piper Jaffray to ” Neutral”. Earlier the firm had a rating of “Overweight ” on the company shares. Piper Jaffray advised their investors in a research report released on Apr 25, 2016.
Many Wall Street Analysts have commented on TrovaGene Inc. Shares were Downgraded by Cantor Fitzgerald on Apr 25, 2016 to ” Hold” and Lowered the Price Target to $ 5 from a previous price target of $9 .Shares were Reiterated by Maxim Group on Feb 3, 2016 to “Buy” and Lowered the Price Target to $ 12 from a previous price target of $13 .
TrovaGene Inc closed down -0.24 points or -3.72% at $6.21 with 4,93,795 shares getting traded on Friday. Post opening the session at $6.44, the shares hit an intraday low of $6.03 and an intraday high of $6.44 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Aug 12, 2015, Stanley Tennant (director) purchased 10,000 shares at $6.06 per share price. According to the SEC, on Aug 12, 2015, Antonius Schuh (CEO) purchased 20,000 shares at $5.45 per share price. On Aug 12, 2015, Steve Zaniboni (CFO) purchased 15,000 shares at $5.43 per share price, according to the Form-4 filing with the securities and exchange commission.
Trovagene Inc. is a development-stage molecular diagnostic company that focuses on the development and commercialization of urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines. The Company’s primary internal focus is to leverage its urine-based molecular diagnostic platform to facilitate improvements in the field of oncology while its external focus includes entering into collaborations to develop its technology in areas such as infectious disease transplant medicine and prenatal genetics. Its cell-free BRAF test confirms the presence of a BRAF V600E mutation in urine DNA at levels of greater than or equal to 0.03% in comparison to the wild-type BRAF genes. Its KRAS mutation assay detects and monitors the seven commonly encountered mutations of the KRAS oncogene. Its urine-based Human Papilloma Virus (HPV) assay identifies women with high grade cervical intraepithelial neoplasia (CIN2/3).